← Back to Screener
Taysha Gene Therapies, Inc. Common Stock (TSHA)
Price$5.95
Favorite Metrics
Price vs S&P 500 (26W)14.59%
Price vs S&P 500 (4W)29.01%
Market Capitalization$1.72B
All Metrics
Book Value / Share (Quarterly)$0.87
P/TBV (Annual)342.79x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)57.53%
Cash Flow / Share (Quarterly)$-0.33
Price vs S&P 500 (YTD)6.45%
Net Profit Margin (TTM)-780.33%
EPS (TTM)$-0.34
10-Day Avg Trading Volume2.76M
EPS Excl Extra (TTM)$-0.34
EPS (Annual)$-0.34
ROI (Annual)-36.65%
Cash / Share (Quarterly)$1.12
Revenue Growth QoQ (YoY)171.27%
ROA (Last FY)-31.75%
Revenue Growth TTM (YoY)17.28%
EBITD / Share (TTM)$-0.37
ROE (5Y Avg)-3789.27%
Operating Margin (TTM)-782.50%
Cash Flow / Share (Annual)$-0.33
P/B Ratio6.98x
P/B Ratio (Quarterly)6.10x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)148.81x
Net Interest Coverage (TTM)-77.24x
ROA (TTM)-38.53%
EPS Incl Extra (Annual)$-0.34
Current Ratio (Annual)12.23x
Quick Ratio (Quarterly)12.10x
3-Month Avg Trading Volume2.93M
52-Week Price Return368.75%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.26
P/S Ratio (Annual)176.37x
Asset Turnover (Annual)0.03x
52-Week High$6.04
EPS Excl Extra (Annual)$-0.34
CapEx CAGR (5Y)55.95%
26-Week Price Return18.58%
Quick Ratio (Annual)12.10x
13-Week Price Return23.46%
Total Debt / Equity (Annual)0.20x
Current Ratio (Quarterly)12.23x
Enterprise Value$1,454.337
Asset Turnover (TTM)0.04x
Book Value / Share Growth (5Y)-34.68%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1115.27%
Cash / Share (Annual)$1.12
3-Month Return Std Dev80.91%
Net Income / Employee (TTM)$-1
ROE (Last FY)-44.14%
Net Interest Coverage (Annual)-65.37x
EPS Basic Excl Extra (Annual)$-0.34
Total Debt / Equity (Quarterly)0.20x
EPS Incl Extra (TTM)$-0.34
ROI (TTM)-45.60%
P/S Ratio (TTM)176.37x
Revenue / Share (Annual)$0.03
Tangible BV / Share (Annual)$0.02
Price vs S&P 500 (52W)338.92%
Year-to-Date Return9.09%
5-Day Price Return29.59%
EPS Normalized (Annual)$-0.34
ROA (5Y Avg)-73.00%
Net Profit Margin (Annual)-1115.27%
Month-to-Date Return34.23%
Cash Flow / Share (TTM)$-2.76
EBITD / Share (Annual)$-0.37
Operating Margin (Annual)-1130.65%
LT Debt / Equity (Annual)0.20x
ROI (5Y Avg)-153.51%
LT Debt / Equity (Quarterly)0.20x
EPS Basic Excl Extra (TTM)$-0.34
P/B Ratio (Annual)6.10x
Pretax Margin (TTM)-780.33%
Book Value / Share (Annual)$0.87
Price vs S&P 500 (13W)22.77%
Beta1.22x
Revenue / Share (TTM)$0.03
ROE (TTM)-56.64%
52-Week Low$1.13
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.25
4.25
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TSHATaysha Gene Therapies, Inc. Common Stock | 176.37x | 17.28% | — | — | $5.95 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Taysha Gene Therapies develops AAV-based gene therapies for monogenic central nervous system diseases, targeting both rare and large patient populations. Its clinical-stage pipeline includes TSHA-102, a self-complementary AAV9 therapy delivered intrathecally for the treatment of Rett syndrome.